Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph 'Disruption' Could Ride On PDUFA Reauthorization's Back

This article was originally published in The Tan Sheet

Executive Summary

Changing the monograph process would be "one example of where disruption can be positive," CEO Scott Melville says at CHPA's executive conference. Legislation that would be added to the PDUFA reauthorization could be the best chance for monograph reform, but will be a lengthy process.

Advertisement

Related Content

OTC Monograph User Fee Goals Document Beats Authorization To Finish Line
OTC Hangover Remedy Safety On Tap For FDA Advisory Committees
OTC Monograph User Fees: FDA-Industry Talks Move From Basics To Details

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS108234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel